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Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV) associated tumor. In addi-
tion to EBV, host genetic factors are believed to be important determinants of NPC risk.
Of all genes studies to date, human leukocyte antigen (HLA) genes have shown the
most consistent evidence for association with NPC, both from candidate-gene studies and
genome-wide association studies (GWAS). In this report we summarize results from recent
studies that evaluated the association between HLA and NPC, and discuss whether find-
ings reflect direct causal associations for HLA genes and/or indirect associations that mark
causal associations with other genes in the gene-dense major histocompatibility (MHC)
region where HLA resides. We also compare GWAS results across cancer sites for which
strong hits in the MHC region were observed to generate new hypotheses regarding the
role of HLA genes in the development of EBV-associated cancers such as NPC. Of note, we
report that MHC associations for EBV-associated cancers (NPC, EBV+Hodgkin lymphoma)
are driven by HLA class I genes. In contrast, MHC associations for other viral-associated
cancers (cervical cancer, hepatocellular carcinoma) or other hematopoetic cancers (EBV−
Hodgkin lymphoma, leukemia, non-Hodgkin lymphomas) are driven by HLA class II genes,
and those for other solid tumors with less clear links to infections (lung, testicular, prostate
cancers) are driven by non-HLA genes in the MHC region. Future studies should aim to
better understand these patterns.
Keywords: genome-wide association study, nasopharyngeal carcinoma, HLA antigens, EBV, infection associated
cancers
INTRODUCTION
Nasopharyngeal carcinoma (NPC) is an epithelial malignancy that
is common in regions of Southeast Asia and the Mediterranean
Basin. The age-adjusted incidence rate of this tumor in South-
ern China, for example, is 25–30 cases per 100,000 person years,
which is approximately 50 times higher than what is observed in
the Western world (1–3). Infection with Epstein–Barr virus (EBV)
is believed to be a near necessary factor for the development of
NPC (3, 4). EBV is a ubiquitous infection that typically occurs
in early life, establishes lifelong latent infection in B-lymphocytes,
and periodically reactivates in the epithelial compartment of the
pharynx (5). Since EBV infection is common and NPC is rare, it
is widely agreed that other environmental and genetic factors are
important determinants of NPC risk. With respect to host genetic
factors associated with NPC, human leukocyte antigens (HLA)
have been proposed to be important, given their central role in
presentation of viral antigens to the immune system (6).
The HLA genes comprise a family of highly polymorphic genes
located within the major histocompatibility complex (MHC)
on chromosome 6p21.3. An association between HLA genes
and NPC was first proposed by Simons and colleagues (7).
Since that initial report, the association between HLA genes
and NPC has been confirmed in over 100 candidate-gene-based
association studies (3, 8, 9). More recently, three independent
genome-wide association studies (GWAS) of NPC consistently
identified SNPs within the MHC region (where HLA genes are
located) as having the strongest evidence for association with
NPC (10–12).
In this review, we summarize recent findings regarding the
association between HLA genes and NPC susceptibility. We then
discuss whether the associations observed in the gene-rich MHC
region, where strong linkage disequilibrium (LD) patterns are
observed,are driven only by HLA genes or whether other non-HLA
genes in the region might also be involved. Finally, we compare
GWAS results across cancer sites for which strong hits in the MHC
region were observed, to generate new hypotheses regarding the
role of HLA genes in the development of EBV-associated cancers
such as NPC.
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HUMAN LEUKOCYTE ANTIGEN ASSOCIATIONS WITH
NASOPHARYNGEAL CARCINOMA
Human leukocyte antigen genes are located within the MHC
region on chromosome 6p21. The MHC region is a gene-dense
region (>150 genes) that also exhibits some of the strongest
LD patterns within the human genome (13). These features of
the MHC region make studies of HLA-cancer association par-
ticularly challenging because it is often difficult to determine
whether reported associations are causal and/or reflect LD with
other genes in this region. Nonetheless, there is a strong bio-
logical a priori for a causal association between HLA genes
and NPC, given that HLA molecules are central to the presen-
tation of viral peptides to cytotoxic and helper immune cells,
and that infection with EBV is ubiquitously associated with
the development of NPC. Of relevance to this review, there
are three classical HLA class I genes, namely, HLA-A, HLA-B,
and HLA-C, and three clusters of classical HLA class II genes,
namely, HLA-DR, HLA-DP, and HLA-DQ that have been eval-
uated for their association with NPC. Both HLA class I and
class II molecules can bind peptides through their peptide recog-
nition groove and present peptides to T cells. However, HLA
class I and II genes differ with respect to the types of cells in
which they are expressed and the types of immune cells they
regulate. HLA class I molecules are expressed on most nucle-
ated cells and typically present foreign peptides to cytotoxic T
cells. HLA class II molecules have a more restricted expression
pattern being normally expressed on B-lymphocytes and antigen-
presenting cells that typically present foreign peptides to helper T
cells (13).
As alluded to in the Introduction, the association between HLA
and NPC was first proposed in 1974 and since that time over
100 candidate-gene association studies have consistently reported
associations between HLA alleles/haplotypes and NPC (3, 8, 9).
More specifically, studies have reproducibly reported associations
with NPC for the following HLA class I alleles: HLA-A*0207 (risk
allele in LD with HLA-B*4601), HLA-A*1101 (protective allele in
LD withHLA-B*13), andHLA-B*5801 (risk allele in LD withHLA-
A*3303) (9, 14). Linkage analyses also suggested that HLA-A and
HLA-B genes are associated with the development of NPC (15–
17). Other HLA genes, including HLA-C and HLA class II genes,
showed less consistent findings across studies (9).
With the advent of technologies to interrogate the entire
genome to better understand the genetic architecture of com-
plex diseases (18), it has become possible to evaluate HLA-
NPC associations in the context of genetic associations in other
regions of the genome. To date, four NPC GWAS have been
reported (10–12, 19). Of these four studies, three reported the
strongest hits in the MHC region, where HLA genes reside
(10–12) and only one GWAS (the smallest with a total of 110
NPC cases and 260 controls in the discovery phase) did not
report genome-wide significant hits in the MHC region (19).
The largest NPC GWAS to date from Guangdong, China (3,477
and 6,570 individuals in discovery and replication phases, respec-
tively) reported their strongest finding to be located in HLA-
A (rs2860580; PGWAS= 1.34× 10−28, Pcombined= 4.88× 10−67,
OR= 0.58; Figure 1, NPCb) (11). The strongest reported asso-
ciations for the Taiwan (562 and 2,275 individuals in dis-
covery and replication phases, respectively) (10) and Guangxi,
FIGURE 1 | GWAS results map in the HLA-A locus. Top: Triangles and
diamonds dots indicate the P values from different GWASs on a minus
logarithmic scale according to the chromosome location of the SNPs.
Different studies are labeled with different colors. Red: NPCa (10); Green:
NPCb (11); Blue: NPCc (12); Orange: EBV+ HL (21). The solid triangles indicate
significant SNPs reported in GWASs. The hollow triangles indicate other SNPs
listed in the supplementary documents. The solid diamonds indicate
significant amino acids located within the HLA genes (12). Bottom: Detailed
LD structure depicted in HaploView using control samples from the NPCa
GWAS (10). The increasing intensities of red represent lower D′ values.
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China (1,043 and 985 individuals in discovery and replication
phases, respectively) (12). NPC GWAS were also located
in HLA-A (Taiwan GWAS: rs2517713, PGWAS= 3.56× 10−8,
Pcombined= 3.90× 10−20, OR= 1.88, Figure 1, NPCa; Guangxi,
China GWAS: rs417162,PGWAS= 1.13× 10−7,Pcombined= 1.05×
10−11, OR= 0.63, Figure 1, NPCc). It is noteworthy to point
out that rs2860580 and rs2517713 are in complete LD, and
that the Guangxi, China GWAS (12) also observed strong
evidence for association for rs2517713 (PGWAS= 3.03× 10−7,
Pcombined= 1.63× 10−11, OR= 0.60, Figure 1, NPCc). While sig-
nificant associations were reported for SNPs in the HLA-B/C
and HLA-DR/DQ regions in the Guangdong, China NPC GWAS
(rs2894207; PGWAS= 1.22× 10−16, Pcombined= 3.42× 10−33,
OR= 0.61; rs28421666;PGWAS= 3.54× 10−9,Pcombined= 2.49×
10−18, OR= 0.67, respectively) (11) they were not as strong as
those observed for SNPs located in HLA-A. Furthermore, in the
Guangxi NPC GWAS (12), where high resolution HLA genotyping
was performed, multivariate analyses suggested that associations
were driven by HLA-A*1101 and that presence of glutamine at
amino acid position 62 of the HLA-A gene (which marks HLA-
A*11) was strongly associated with NPC risk providing a biological
basis for the SNP-based associations reported.
Taken together, findings from both candidate-gene-based
studies and GWAS have consistently demonstrated associations
between HLA genes and NPC. The strongest evidence for asso-
ciation has been observed for alleles within HLA class I genes,
including HLA-A*0207 (risk allele in LD with HLA-B*4601),
HLA-A*1101 (protective allele in LD with HLA-B*13), and HLA-
B*5801 (risk allele in LD with HLA-A*3303). The associations
are biologically plausible and suggest a direct causal association
defined by specific amino acids involved in defining HLA binding
specificities.
NON-HUMAN LEUKOCYTE ANTIGEN ASSOCIATIONS IN THE
MHC REGIONWITH NASOPHARYNGEAL CARCINOMA
In addition to HLA genes, other genes in the MHC region of
chromosome 6p21.3 have been found to be associated with NPC.
Notably, results from the Taiwan NPC GWAS (10) suggested
significant associations for the HLA complex group 9 (HCG9)
gene (rs9260734,PGWAS= 2.49× 10−7,Pcombined= 6.77× 10−18,
OR= 1.85), and the gamma-aminobutyric acid (GABA) B
receptor 1 (GABBR1) gene (rs29232, PGWAS= 1.67× 10−8
Pcombined= 8.97× 10−17, OR= 1.67). These associations were
also observed in the two NPC GWAS from China (11, 12), sug-
gesting that the associations observed are real and not driven
by chance. Given the strong LD patterns observed in the MHC
region, however, the issue of whether these associations implicate
new genes involved in NPC or mark one or more of the HLA
associations discussed above is still an open question.
HCG9 is a non-protein coding gene located within 30 kb of
the HLA-A gene. Given its close proximity to HLA-A and lack
of known function, it is hypothesized that SNPs within this gene
reported to be associated with NPC in recently published GWAS
reflect LD with causal polymorphisms withinHLA-A. In fact, mul-
tivariate analyses of data from the Taiwan (10) and two China
(11, 12) GWAS suggested that hits within the HCG9 region are
not independent of the HLA-A findings. Furthermore, a recent
pooled analysis of two NPC case-control studies in Taiwan that
jointly evaluated HLA and HCG9 confirmed that the HCG9 signal
observed in the original Taiwan GWAS is likely to be driven by
HLA rather than an independent signal (20).
In contrast to HCG9, GABBR1 encodes a G protein-coupled
receptor that forms a heterodimer with GABAB receptor 2, thereby
triggering downstream signaling events in the proliferation, dif-
ferentiation, and migration of cancer cells. This known biological
function provides some a priori support for a possible functional
role of GABBR1 in cancer development. Following the initial Tai-
wan GWAS finding, sequencing of full-length GABBR1 genes,
including the rs29232 region, was performed in 37 NPC cases with
high-risk haplotypes and 48 controls. No germ line mutations were
detected and most of the novel association signals either failed to
be validated or did not reach the statistical significance of rs29232
(10). However, in this same study expression of the GABBR1 pro-
tein in NPC tissues was also evaluated using immunohistochemical
staining and the intensity of the GABBR1 signal in tumor cells was
significantly higher than that detected in adjacent normal epithe-
lial cells (P < 0.001) (10). This finding provides additional support
for a potential functional role for GABBR1 in the etiology of NPC.
Statistical approaches have also been employed in an attempt to
determine whether GWAS findings in HLA-A and GABBR1 repre-
sent distinct, independent associations, or whether they represent
a single association marked by SNPs in both gene regions. Results
from these efforts have been mixed, however, multivariate logistic
regression analysis of the Taiwan GWAS data indicated that the
GABBR1 signal (rs29232) remained significant after controlling
for the effect of HLA-A GWAS SNPs and sequence-based HLA-
A alleles, namely, HLA-A*0207/0215N or HLA-A*110101/0121N
(10). Similar efforts from the two China GWAS, however, sug-
gested that the GABBR1 effect was largely driven by the HLA-A
SNPs/alleles (11, 12). An analysis of pooled data from two NPC
case-control studies conducted in Taiwan that jointly evaluated
HLA-A andGABBR1 reported that while the effect of GABBR1was
attenuated by adjustment for HLA-A alleles, a significant effects
for GABBR1 (rs29232) remained after adjustment for HLA-A and
that an independent effect of GABBR1 could therefore not be ruled
out (20).
In summary, while HLA genes, and HLA-A in particular, likely
explain much of the signals observed from NPC GWAS in the
MHC region on chromosome 6p21.3, the possibility that other
genes in the region, such as GABBR1, might also be causally
involved in NPC cannot be discarded at this time.
HUMAN LEUKOCYTE ANTIGEN ASSOCIATIONS IN OTHER
CANCER GENOME-WIDE ASSOCIATION STUDIES
Close to 180 cancer GWASs have been published (NHGRI GWAS
catalog1). We reasoned that examination of findings from the
MHC region across these GWAS might provide interesting clues
into the link between HLA genes and infection-associated can-
cers such as NPC. We therefore summarized findings within the
MHC region from cancer GWAS available through the NHGRI
GWAS catalog1. To organize our review, we classified cancers
into mutually exclusive groups as follows: EBV-associated cancers
[including NPC, classical Hodgkins lymphoma (HL), and gastric
1http://www.genome.gov/gwastudies
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cancer], other infection-related cancers [including cervical can-
cer and hepatocellular carcinoma (HCC)], other immune-related
(hematopoetic) tumors [including various subtypes of non-
Hodgkin lymphomas (NHL)], and other solid tumors (including
lung, testicular, and prostate cancers). While these groupings are
somewhat arbitrary (e.g., we grouped gastric cancers with EBV-
associated cancers despite its strong link with H. pylori infection
since approximately 8% of gastric cancers are known to be EBV-
positive and the focus of this review is on NPC, another EBV-
associated cancer), we believe that they provide a useful rubric for
summarizing findings across a diverse set of cancers. We focused
our review on the MHC region alone (defined as chr6: 29 –33 Mb)
and considered as significant SNPs with a reported P-value for
association <5× 10−7. Findings are summarized in Table 1.
First, we considered cancers that are known to be linked to EBV
infection (Table 1). In addition to NPC (for which nearly 100% of
tumors are EBV-associated), we evaluated two cancers for which
a proportion of tumors are known to be EBV-associated: HL and
gastric cancer. Burkitt lymphoma (BL) was not considered despite
its close association with EBV infection because no BL GWAS has
been published to date. As discussed in previous sections of this
review, results from NPC GWAS indicate that the strongest evi-
dence for an association are with HLA-A, an HLA class I gene.
Findings from HL GWAS suggest an interesting pattern. The sin-
gle GWAS that evaluated EBV(+) and EBV(−) HL separately (21)
found evidence for an HLA class I association for EBV(+) HL and
for an HLA class II association for EBV(−) HL. The HLA class I
association observed for EBV(+) HL is consistent with findings
for NPC. The HLA class II association observed for EBV(−) HL
is consistent with findings for other hematopoetic cancers and
cancers caused by infections other than EBV (discussed further
below). A second HL GWAS that did not stratify by EBV status
provides evidence for association with HLA class II but failed to
observe and association with HLA class I (22). Finally, a GWAS that
focused on nodular sclerosis HL, a subtype of HL thought not to be
EBV-associated, also reported associations with HLA class II genes
only (23). This highlights the importance of stratifying analyses on
viral status for this heterogeneous disease. Finally, four gastric can-
cer GWAS have been published (24–27). None reported evidence
for a significant association within the MHC region. It should be
noted, however, that <10% of gastric cancers are EBV(+) and so
the lack of association observed within the MHC might reflect
the lack of stratification on EBV status rather than a true lack
of association for EBV(+) gastric cancers. In summary, GWAS
of EBV(+) cancers have consistently reported associations in the
MHC region, and within the MHC the strongest evidence points
to an important role for HLA class I genes.
Next, we evaluated results from GWAS for other infection-
associated cancers (Table 1). Of the cancers with proven link to
viral infections other than EBV, GWAS have been reported for cer-
vical cancer (linked to human papillomavirus infection) and HCC
(linked to hepatitis B and C infections, HBV and HCV respec-
tively). Two cervical cancer GWAS reported the strongest evidence
for association within the HLA class II region of the MHC (28,
29). The four HCC GWAS that specifically evaluated HCV-related
or HBV-related cancers all reported strong hits within the HLA
class II region (30–33). In contrast, the one HCC GWAS that did
not stratify by virus status (34) observed evidence for association
within the MHC region, but failed to report significant associa-
tions within HLA, again highlighting the importance of stratifica-
tion by viral status for etiologically heterogeneous tumors. Of note,
none the four GWAS of gastric cancer, a cancer linked with infec-
tion with the bacteriaHelicobacter pylori, reported significant asso-
ciations within the MHC region, suggesting differences in the HLA
associations observed for bacterial- versus viral-associated can-
cers. In summary, all GWAS of non-EBV virus infection-associated
cancers (HPV, HBV, and HCV) that specifically considered viral
status reported evidence for HLA class II associations with dis-
ease. This contrasts with EBV-associated cancers, where evidence
consistently points to HLA class I involvement.
Finally, we examined GWAS for other hematopoetic and solid
tumors (Table 1). Again, clear and consistent patterns emerged.
For other hematopoetic tumors, signals observed in the MHC
region were consistently located within the HLA class II region
or outside of the HLA class I or II regions. In contrasts, for other
solid tumors for which significant signals were observed in the
MHC region, the observed signals were consistently located out-
side of the HLA class I or II regions and appeared to involve
non-HLA genes. The one exception to this was the HLA class
II (rs2395185) association observed for lung cancer in never-
smoking woman in Asia (35). It should be noted that, in contrast
to observations for infection-associated cancers, significant MHC
signals were not always observed for other hematopoetic and solid
tumors. For example, amongst hematopoetic tumors, no evidence
for significant associations within the MHC region were reported
for GWAS of childhood acute lymphoblastic leukemia (36–39),
chronic myeloid leukemia (40), and diffuse large B-cell lymphoma
(41). For other solid tumors, no evidence for significant associa-
tions within the MHC region were reported for GWAS of basal
cell carcinoma, bladder cancer, breast cancer, colorectal cancer,
endometrial cancer, esophageal cancer, Ewing sarcoma, gallblad-
der cancer, glioblastoma, glioma, melanoma, multiple myeloma,
neuroblastoma, ovarian cancer, ovarian reserve, pancreatic cancer,
renal cell carcinoma, small-cell lung cancer, testicular cancer, thy-
roid cancer, urinary bladder cancer, and Wilms tumor (NHGRI
GWAS catalog1).
Taken together, the present review of published cancer GWAS
suggests that:
1. HLA class I genes are important for EBV-associated cancers.
2. HLA class II genes are important for HPV, HBV, and HCV-
associated cancers.
3. HLA class II and/or non-HLA genes in the MHC region
explain associations within the MHC for other hematopoetic
malignancies, and
4. There is less evidence for HLA (class I or II) involvement in the
development of other solid tumors.
Particularly striking was the tendency for EBV-associated can-
cers to be linked to HLA class I genes, while other cancers had
stronger evidence for HLA class II gene associations (HPV, HBV,
and HCV-associated cancers; and some hematopoetic malignan-
cies) or for the involvement of non-HLA genes in the MHC region
(other solid tumors and some hematopoetic malignancies). We
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therefore considered further the characteristics of EBV infection
that might explain the “predilection” of EBV-associated cancers to
be associated with HLA class I genes.
Little is known about the genetic basis for immunological
responses to EBV infection, despite the belief that such responses
are important mediators of cancer risk. The only published GWAS
that evaluated genetic factors associated with antibodies against
EBV reported evidence for the involvement of HLA class II genes
in EBV seroreactivity, measured as anti-EBV EBNA-1 IgG levels
(42). This finding appears at face value to be inconsistent with
the strong HLA class I association observed for NPC, but needs
to be interpreted with caution since the anti-EBV antibody evalu-
ated (IgG against EBNA-1) is not a good marker of NPC risk. In
the future, it will be important to evaluate genetic factors associ-
ated with anti-EBV EBNA-1 and VCA IgA responses because (1)
EBNA-1 and VCA are the antigens for which strong and consistent
associations with risk of NPC development have been observed
and (2) IgA responses (rather than IgG responses) are thought to
better reflect chronic EBV reactivation at mucosal surfaces believed
to be required for NPC development.
One hypothesis to explain the specific association of HLA class
I genes with EBV-associated cancers while HPV, HBV, and HCV-
associated cancers have more clear associations with HLA class II
genes invokes site of infection. Of all infectious agents known to
be directly linked to cancer, EBV is the only one that establishes
lifelong latency in B-lymphocytes and requires infection of the
epithelial compartment during lytic reactivation for viral shed-
ding and transmission. Perhaps HLA class I genes are important
mediators of this complex biological lifecycle, although precisely
how this might be remains to be established. Of interest to note
in this respect is the fact that progression to AIDS among HIV
infected individuals has been consistently shown to be associated
with HLA class I alleles (43). Since HIV is a virus that, like EBV,
establishes lifelong infection in lymphocytes, the commonality of
these findings might suggest a parallel HLA-mediated immuno-
logical response pathway for these two pathogens that is distinct
from that for other infectious agents linked to cancer development.
CHALLENGES AND OPPORTUNITIES
Human leukocyte antigen genes have long been suggested to be
associated with NPC risk. Recent NPC GWAS have confirmed this
association and have further indicated that the strongest genetic
associations with NPC reside within HLA class I genes, particu-
larly HLA-A. This contrasts with what has been observed for other
tumors, suggesting a unique relationship between EBV and HLA
class I genes and the need for studies to more specifically define
how and which host genetic differences in antigen presentation
of specific EBV antigens affects the EBV tumorigenesis process by
promoting viral escape of host immune surveillance leading to
NPC. These studies could provide clues not only about EBV and
NPC, but also about the relationship between other oncogenic
infectious agents and their respective cancers and on the nature of
HLA associations for hematopoetic malignancies.
While challenges remain, given the strong LD patterns observed
in the MHC, the large number of genes in this region and the
highly polymorphic nature of HLA genes themselves, the prospect
of studying diverse populations with distinct HLA patterns and
LD structure, and of applying new technologies such as high-
throughput sequencing and molecular profiling techniques to elu-
cidate the complex structure of the MHC and its association with
NPC and other cancers could lead to better insights into our under-
standing of the specific mechanisms involved in cancer pathogen-
esis. This, in turn, could lead to new interventions aimed at inter-
rupting this pathogenic process as a cancer prevention measure.
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